LOXL2 drives MSC differentiation into CAFs and contributes to MPN progression by modulating peripheral stromal cells; LOX inhibitors and LOXL2 inhibitors are being tested for targeted MPN treatment (35–37). This evidence concerns the gene LOXL2 and myeloproliferative disorder.